Back to Agenda
WHO/Swissmedic Signature Session - Towards Access 2030: How Can Strengthening of Regulatory Systems Contribute?
Session Chair(s)
Petra Doerr, PHARMD, RPH
Director, European Directorate for the Quality of Medicines and Healthcare (EDQM), France
Murray M. Lumpkin, DrMed, MD, MSC
Deputy Director, Integrated Development, Lead for Global Reg Systems Initiative , Bill and Melinda Gates Foundation, United States
Various initiatives and programs are under way to improve access to quality medicines in low- and middle-income countries (LMIC). An important component of achieving this goal is to strengthen the regulatory systems of those countries. Many stakeholders (and many resources) are involved and engaged. However, what does Regulatory Systems Strengthening (RSS) actually mean in the context of Access 2030 in LMICs and do all these efforts show tangible results? What are the outcomes we are trying to achieve through RSS and how can we improve these outcomes?
Speaker(s)
Emer Cooke, MBA, MSC
Chair, ICMRA; Executive Director, European Medicines Agency, Netherlands
Towards access 2030: An Overview of WHO Efforts in Regulatory Systems Strengthening
Delese Mimi Darko, MBA, RAC
Director General, African Medicines Agency (AMA) , Rwanda
What Can Regulators in LMIC Do to Better Utilize the Scarce Resources in Order to Improve the Access to Priority Medicines?
Thomas B. Cueni, MBA
Director General, IFPMA, Switzerland
Panel Discussion
Petra Doerr, PHARMD, RPH
Director, European Directorate for the Quality of Medicines and Healthcare (EDQM), France
Panel Discussion
Guido Rasi, MD
Chairman,Clinical Trial Center of Gemelli Polyclinic Inst; Prof of Microbiology, Tor Vergata University of Rome, Italy
Panel Discussion
Nicola Bedlington
Special Advisor, European Patient's Forum, Belgium
Panel Discussion
Alex Schulze
Co-Head Division Global Programme Health, Swiss Agency For Development Cooperation, Switzerland
Panel Discussion
Hiiti Sillo, MSC, RPH
Unit Head, Regulation and Safety, Department of Regulation and Prequalification, World Health Organization (WHO), Switzerland
Panel Discussion
Nathalie Strub Wourgaft
Medical Director, Drugs For Neglected Diseases Initiative (dndi), Switzerland
Panel Discussion
Have an account?